|
FBXO34 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.35930000003215E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.34550000000056E-05 |
| Normal-vs-Stage2 |
2.20829999999506E-05 |
| Normal-vs-Stage3 |
3.64439999955835E-07 |
| Normal-vs-Stage4 |
1.004499999957E-06 |
| Stage1-vs-Stage2 |
3.193800E-01 |
| Stage1-vs-Stage3 |
2.196400E-01 |
| Stage1-vs-Stage4 |
9.474300E-02 |
| Stage2-vs-Stage3 |
9.472200E-01 |
| Stage2-vs-Stage4 |
7.462400E-01 |
| Stage3-vs-Stage4 |
6.463600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.94059999994545E-06 |
| Normal-vs-AfricanAmerican |
2.165800E-02 |
| Normal-vs-Asian |
3.58460000000616E-05 |
| Caucasian-vs-AfricanAmerican |
2.676200E-01 |
| Caucasian-vs-Asian |
9.145400E-01 |
| AfricanAmerican-vs-Asian |
2.492200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.67319999999838E-05 |
| Normal-vs-Female |
1.92089999995204E-06 |
| Male-vs-Female |
5.180600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.63949999999869E-05 |
| Normal-vs-Age(41-60Yrs) |
1.59780999999803E-05 |
| Normal-vs-Age(61-80Yrs) |
4.95550000034761E-07 |
| Normal-vs-Age(81-100Yrs) |
4.141300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.219000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.050200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.638950E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.320200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.455800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.183000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.364300E-02 |
| Classical-VS-Follicular |
4.059200E-03 |
| Classical-VS-Other |
9.096600E-01 |
| Classical-VS-Normal |
1.406730E-04 |
| Tall-VS-Follicular |
8.156600E-01 |
| Tall-VS-Other |
5.179600E-01 |
| Tall-VS-Normal |
4.15200000003502E-06 |
| Follicular-VS-Other |
3.281400E-01 |
| Follicular-VS-Normal |
4.56969999951262E-07 |
| Other-VS-Normal |
1.533600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.0808999967592E-08 |
| Normal-vs-N1 |
2.40399999995589E-06 |
| N0-vs-N1 |
4.345200E-01 |
|
|
